Novartis to Acquire Presbyopia Drug Developer Encore Vision

Wednesday, December 21 2016 | 00 h 00 min | Agreements and Acquisitions, News, Press Release

Novartis Ophthalmology announced they have entered into an agreement to acquire a topical treatment for presbyopia from Encore Vision Inc., a privately-held Texas based company. The announcement calls the new investigational product EV06 a “potentially disruptive innovation” and the first-in-class topical treatment for presbyopia.

EV06 has completed a phase I/II proof of concept study. The pro-drug restores the bilateral micro-fluidics of the crystalline lens through a biochemical mechanism of action.

In 2016, Novartis combined its retina medicines business with the Alcon pharmaceuticals business, now operating as one Ophthalmology franchise under Novartis Pharmaceuticals.

View the Novartis Press release here.

View Encore Vision’s discussion of the drug and clinical trials HERE.

Prada Group and EssilorLuxottica Announce Ten-year Licensing Renewal

The renewal is a testament to strong confidence, trust and collaboration between the two companies

Learn More

EssilorLuxottica’s greenhouse gas emissions reduction targets validated by the Science Based Targets Initiative (SBTi)

This marks a key milestone in the Company’s efforts to reduce the environmental impact across its entire value chain.

Eye-Opening Education at Vision Expo East 2025

Vision Expo East 2025 will offer new conference programming for professional development in the eyecare and eyewear industry, offering over 270 hours of accredited and non-accredited education tailored to the needs of ophthalmologists, optometrists, opticians and allied professionals.

EssilorLuxottica Signs Agreement to Acquire Espansione Group for Accelerating Its Growth in the Med-tech Space

EssilorLuxottica strengthens its portfolio of advanced high-quality vision care instruments and certified medical technologies, with innovative solutions for dry-eye and other diseases

NOW Trend Showcase Submission Deadline Extended to January 2025

The submission deadline for the NOW Trend Showcase and Awards at Vision Expo East 2025 has been extended to January 17, 2025.

Prada Group and EssilorLuxottica Announce Ten-year Licensing Renewal

The renewal is a testament to strong confidence, trust and collaboration between the two companies

Learn More

EssilorLuxottica’s greenhouse gas emissions reduction targets validated by the Science Based Targets Initiative (SBTi)

This marks a key milestone in the Company’s efforts to reduce the environmental impact across its entire value chain.

Eye-Opening Education at Vision Expo East 2025

EssilorLuxottica Signs Agreement to Acquire Espansione Group for Accelerating Its Growth in the Med-tech Space

EssilorLuxottica strengthens its portfolio of advanced high-quality vision care instruments and certified medical technologies, with innovative solutions for dry-eye and other diseases

NOW Trend Showcase Submission Deadline Extended to January 2025

The submission deadline for the NOW Trend Showcase and Awards at Vision Expo East 2025 has been extended to January 17, 2025.

Prada Group and EssilorLuxottica Announce Ten-year Licensing Renewal

The renewal is a testament to strong confidence, trust and collaboration between the two companies

Learn More

EssilorLuxottica’s greenhouse gas emissions reduction targets validated by the Science Based Targets Initiative (SBTi)

This marks a key milestone in the Company’s efforts to reduce the environmental impact across its entire value chain.

Eye-Opening Education at Vision Expo East 2025

EssilorLuxottica Signs Agreement to Acquire Espansione Group for Accelerating Its Growth in the Med-tech Space

EssilorLuxottica strengthens its portfolio of advanced high-quality vision care instruments and certified medical technologies, with innovative solutions for dry-eye and other diseases

NOW Trend Showcase Submission Deadline Extended to January 2025

The submission deadline for the NOW Trend Showcase and Awards at Vision Expo East 2025 has been extended to January 17, 2025.

Prada Group and EssilorLuxottica Announce Ten-year Licensing Renewal

The renewal is a testament to strong confidence, trust and collaboration between the two companies

Learn More

EssilorLuxottica’s greenhouse gas emissions reduction targets validated by the Science Based Targets Initiative (SBTi)

This marks a key milestone in the Company’s efforts to reduce the environmental impact across its entire value chain.

Eye-Opening Education at Vision Expo East 2025

EssilorLuxottica Signs Agreement to Acquire Espansione Group for Accelerating Its Growth in the Med-tech Space

EssilorLuxottica strengthens its portfolio of advanced high-quality vision care instruments and certified medical technologies, with innovative solutions for dry-eye and other diseases

NOW Trend Showcase Submission Deadline Extended to January 2025

The submission deadline for the NOW Trend Showcase and Awards at Vision Expo East 2025 has been extended to January 17, 2025.

Novartis to Acquire Presbyopia Drug Developer Encore Vision

Featured Posts